Senior Director, Financial Investments at Novo Holding A/S
This person is connected to 90 people.
Managing Partner NOVO Ventures at Novo Holding A/S
Senior Partner NOVO Ventures at Novo Holding A/S
Professional at Novozymes Biotech, Inc.
Finance Controller at Novo Nordisk Fonden
Managing Director at Vivo Capital LLC
Member of the Editorial Board at Expert Opinion on Therapeutic Patents Journal
Partner, Seed Investments at Novo Holding A/S
Venture Partner NOVO Ventures at Novo Holding A/S
Director, Principal Investments at Novo Holding A/S
Senior Director Principal Investments at Novo Holding A/S
Paths to Johan Brønnum-Schou
Connections via Relationship Science
Copenhagen Business School, also known as CBS, is situated in Copenhagen, Denmark. CBS was established in 1917 by Danish Society for the Advancement of Business Education and Research(FUHU), however, it wasn't until 1920 that accounting became the first full study programme at CBS. Today CBS has more than 20,000 students, 13,000 employees and offers a wide range of undergraduate and graduate programmes within business all with an interdisciplinary and international focus. CBS' campus is located in the district of Frederiksberg and centers on CBS' main campus Solbjerg Plads (finished in 2000).
Since the Danish Universities Act of 2003 CBS has had a Board of Directors with an external majority. The Board of Directors appoints the President of CBS, who is currently Per Holten-Andersen.
Investment Director, Finance
2008 - Current
Novo is an active, long-term manager which aims to support sustainable partnerships through the advancement of life sciences, investing more than half of their capital in North American companies and the rest in Denmark and Europe. The firm invests across technologies, products and financial stages, including providing funds for embryonic start-ups in extraordinary situations.Novo makes typical equity investments of 1-15 million euros, focusing on investee companies with significant profit and growth potential within the following areas: products that diagnose, control, treat and prevent disease; biotechnology development and applications; instruments and medical devices; improvement of food, nutrition and health for humans and animals and development of sustainable solutions for the environment.The firm typically takes a minority position in their investee companies, seeking to provide value-adding support in areas such as intellectual property rights, scientific evaluation, strategic business development, licensing and collaborations and financing strategies through their extensive network and active participation on the board of directors. Their typical exit strategies include IPOs, trade sales and mergers.The financial investments of Novo A/S comprise a portfolio of well-diversified assets, including liquid and listed equities, Danish government and mortgage bonds and high-yielding credit and emerging markets bonds. The firm seeks to spread risk by diversifying the Novo Nordisk Foundation's assets and creating a pool of liquid reserves which can be used to support Novo Group companies.
Senior Director, Financial Investments
Novo Holding A/S provides financial investments and manages the Novo Nordisk Foundation’s assets. It offers seed and venture capital to development stage companies and takes ownership positions in companies within life science and biotechnology. The company was founded on September 8, 1999 and is headquartered in Hellerup, Denmark.
You've reached your 7 free profiles limit this month.
Upgrade to RelSci Pro today to enjoy unlimited profile views and much more!